Friday, Oct 20, 2023 · SEC filings
What the smart money revealed on Oct 20
137 insider filings came in. We hid 18 planned (10b5-1) sellers and 81 people whose filings were routine, like grants and tax withholding.
Protalix BioTherapeutics (PLX) President and CEO Dror Bashan bought $90.5K
64,516 shares on the open market. Not a grant or an option exercise.
Central Securities (CET) Vice President Andrew O'Neill bought $70K
1,954 shares on the open market. Not a grant or an option exercise. Their past buys: 3 of 4 checked quarters beat the typical stock 6 months later.
US Bancorp (USB) Vice Chair James Kelligrew bought $281K
Open-market buys of more than one share class. Not a grant or an option exercise. Filed late: $281K of it was bought Nov 18–Jul 6. Form 4s are due 2 business days after a trade.
Atlassian (TEAM) Co-CEO Michael Cannon-Brookes sold $1.61M
Not marked as a planned 10b5-1 sale. Sold 2% of the shares they held directly. Still holds 403,809 shares.
Atlassian (TEAM) Co-CEO Scott Farquhar sold $1.61M
Not marked as a planned 10b5-1 sale. Sold 2% of the shares they held directly. Still holds 403,809 shares.
Citigroup (C) Head of Markets Andrew Morton sold $1.14M
Not marked as a planned 10b5-1 sale. Sold 6% of the shares they held directly. Still holds 410,060 shares.
Show 3 more real buys
Show 12 more real sales
13F season
Holdings as of Sep 30, 2023 are due Nov 14
40 funds have filed so far. 40 filed for the quarter before.
Biggest real insider buys, Oct 14–20
Open-market buys by officers and directors, filed in the 7 days up to Oct 20.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.